Biogen used unlawful, anticompetitive agreements with key pharmacy benefit managers to block the distribution of US generic versions of its Tecfidera (dimethyl fumarate) while it “scrambled” to switch the market to its follow-on brand Vumerity (diroximel fumarate) for multiple sclerosis, according to a class action lawsuit.
Filed by health-benefit plan Local No. 1 Health Fund in the US District Court for the Northern District of Illinois,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?